Table II:

Key clinical trials of checkpoint inhibitors in the neoadjuvant setting

Trial	Drug	Phase	Setting	Size	pCR
KEYNOTE-173[41]	Pembrolizumab + nab-paclitaxel or paclitaxel +/− carboplatin +AC	Ib	Early-stage TNBC	N = 60	60%
KEYNOTE-522[42]	Pembrolizumab or placebo + paclitaxel, carboplatin, doxorubicin or epirubicin, cyclophosphamide	III	Untreated stage II-III TNBC	N = 602	65% (pembro) vs. 51% (placebo)
I-SPY2[43]	Pembrolizumab + paclitaxel, doxorubicin, cyclophosphamide	II	Stage II-III, HER2-negative	N = 250	44% (pembro) vs. 17% (no pembro)
GeparNuevo[27]	Durvalumab or placebo + nab-paclitaxel, epirubicin, cyclophosphamide	II	Primary non-metastatic TNBC	N = 174	61% (durval) vs. 41% (placebo) in window cohort only
IMpassion031[44]	Atezolizumab or placebo + nab-paclitaxel, doxorubicin, cyclophosphamide	III	Stage II-III TNBC	N = 333	58% (atezo) vs. 41% (placebo)

TNBC = triple-negative breast cancer; pCR = pathologic complete response.